查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018083

植入式心臟整流去顫器市場：按產品類型、適應症、技術和最終用戶分類－2026-2032年全球市場預測

Implantable Cardioverter Defibrillators Market by Product Type, Indication, Technology, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，植入式心臟整流去顫器(ICD) 市值將達到 50 億美元，到 2026 年將成長至 52.8 億美元，到 2032 年將達到 76.6 億美元，複合年成長率為 6.28%。

主要市場統計數據
基準年 2025 50億美元
預計年份：2026年 52.8億美元
預測年份 2032 76.6億美元
複合年成長率 (%) 6.28%

簡要概述設備創新、不斷發展的臨床實踐以及醫療保健系統面臨的壓力如何重塑 ICD 治療的作用和提供方式。

植入式心臟整流去顫器（ICD）是現代心臟醫學的基石，為有猝死風險的患者提供挽救生命的治療。過去十年間，在材料科學、電池技術、感測演算法和通訊技術的推動下，ICD 的設計、植入技術和輔助監測都取得了顯著進展。這些創新正在改變患者的選擇、追蹤模式和臨床結果，同時也催生了電生理學、設備工程和數位健康之間的新交叉領域。

技術突破、不斷發展的臨床方案和醫療保健服務體系的變革如何從根本上重新定義 ICD 治療和醫療保健提供者的優先事項。

由於技術、臨床和系統性因素的共同作用，ICD治療正經歷變革性時期。小型化和皮下植入式設計降低了手術複雜性和器械相關感染疾病，而導線技術和感測演算法的進步提高了心律不整識別的準確性，並減少了不必要的治療。除了硬體創新之外，軟體改進和基於雲端的遠端監測也實現了長期數據收集，促進了預防性器械管理，並透過與遠端保健的整合提高了患者的參與度。

本檢驗了近期關稅政策和貿易趨勢如何重塑整個 ICD 價值鏈的供應策略、成本壓力和臨床准入考量。

關稅措施和貿易政策變化對植入式心臟裝置（ICD）生態系統的累積影響，正為製造商、經銷商和醫療保健系統帶來新的挑戰。關稅波動影響半導體晶片、電池材料和電子子組件等上游組件的成本，進而影響籌資策略和供應商多元化。為此，製造商正在重新評估其採購地點並審查供應契約，以減輕貿易波動的成本影響。

將產品架構、臨床適應症、底層技術和醫療保健環境與採用促進因素和策略機會連結起來的詳細細分分析。

細分市場分析表明，推動產品普及和臨床效用的因素因產品類型、治療適應症、底層技術和醫療環境而異。按產品類型分類，市場包括皮下植入式心臟復律去顫器 (ICD)、經靜脈植入式心臟復律去顫器 (ICD) 和穿戴式式心臟復律去顫器 (ICD)，每種產品都滿足不同的臨床需求。皮下植入式系統優先考慮感染預防和減少血管內硬體；經靜脈植入式裝置提供起搏治療和更先進的節律管理功能；穿戴式解決方案則在高風險時期提供臨時保護或支援。按適應症分類，患者診療路徑圍繞一級和二級預防模式構建，決策演算法強調風險分層、合併症情況和預期壽命等因素，這些因素有助於確定植入的適用性和時機。

區域趨勢和實施路徑的差異凸顯了報銷制度、監管成熟度和醫療保健服務模式如何影響 ICD 的取得和採用。

區域趨勢凸顯了部署模式、報銷環境和法規結構的多樣性，這些因素共同塑造了各地區的ICD策略。在美洲，成熟的報銷途徑和高手術量與日益成長的成本控制和基於價值的採購理念並存，這要求器械供應商證明其產品具有相對療效和長期性能。歐洲、中東和非洲（EMEA）地區則呈現出監管成熟度和醫療資金籌措模式的多元化格局，一些市場迅速採用MRI兼容性等先進功能，而另一些市場則優先考慮基本可及性和可負擔性，因此需要差異化的市場准入和定價策略。

企業的關鍵競爭和策略趨勢凸顯了產品創新、夥伴關係、臨床證據和供應鏈韌性等因素如何帶來商業性優勢。

植入式心臟復律去顫器 (ICD) 領域的競爭格局以持續投資於漸進式創新、策略夥伴關係和選擇性整合為特徵。老牌製造商不斷投資新一代導線設計、電池化學和感測演算法，以延長設備壽命並減少不利事件。同時，新參與企業和中小企業則專注於穿戴式去心房顫動和以軟體為中心的監測平台等細分創新，這些平台可與醫療管理系統整合。醫療設備製造商與數位醫療公司之間的策略合作正在迅速提升預測分析和遠端監測儀錶板等功能，從而將價值主張從獨立設備轉向完整的醫療解決方案套件。

制定切實可行的策略重點，協調臨床證據產生、產品設計和供應鏈敏捷性，加快部署速度，並維持商業性韌性。

產業領導者應採取整合策略，將產品開發、臨床證據策略和供應鏈韌性結合，以確保永續的競爭優勢。優先投資於能夠顯著降低手術併發症並改善患者體驗的技術，同時確保臨床試驗和註冊研究的設計能夠捕捉到對支付方和醫療服務提供者至關重要的終點指標。此外，還應實現籌資策略多元化，並考慮區域組裝和契約製造，以降低關稅和貿易政策波動帶來的風險，同時確保產品品質和合規性。

透過結合專家訪談和系統的二手文獻綜述，調查方法，確保了可靠和實用的知識。

本報告的研究結合了對臨床和商業專家的定性訪談和對同行評審文獻、監管文件和臨床試驗註冊資訊的整合，以確保觀點平衡且基於證據。主要研究包括對電生理學家、醫療設備診所經理、採購負責人和供應鏈負責人的訪談，以了解真實的臨床實踐模式和決策標準。此外，還系統地審查了包括技術評估、安全性概況和比較分析第二手資料，以從多方面檢驗研究結果，並支持每個主題的研究結論。

一份簡潔、全面的分析報告，闡述了創新、證據和營運準備的策略平衡，這對於負責任且有效地推進 ICD 治療至關重要。

植入式心臟整流去顫器（ICD）領域正處於一個轉折點，其特點是技術取得了顯著進步，醫療服務模式發生了轉變，同時供應鍊和政策風險也日益受到關注。設備設計和遠端功能的進步為改善患者預後和簡化追蹤流程提供了明確的機遇，但要實現這些益處，需要持續的證據支持、靈活的商業策略和穩健的營運系統。能夠積極將臨床需求與可操作的服務模式結合的醫療系統和製造商，最有能力在控制成本和應對准入壓力的同時，創造價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：植入式心臟整流去顫器市場：依產品類型分類

  • 皮下植入式心臟復律去顫器
  • 經靜脈植入式心律轉復除顫器
  • 穿戴式植入式心律轉復除顫器

第9章：植入式心臟整流去顫器市場：依適應症分類

  • 第一級預防
  • 二級預防

第10章：植入式心臟整流去顫器市場：依技術分類

  • 與核磁共振相容
  • 遠端監控支援

第11章：植入式心臟整流去顫器市場：依最終用戶分類

  • 門診手術中心
  • 心臟護理中心
  • 診所
  • 醫院

第12章：植入式心臟整流去顫器市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：植入式心臟整流去顫器市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：植入式心臟整流去顫器市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國植入式心臟整流去顫器市場

第16章：中國植入式心臟整流去顫器市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Angiplast Pvt Ltd.
  • Atrium Medical, Inc.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • ConMed Corporation
  • ConvaTec Group PLC
  • Cook Medical Inc.
  • Fresenius Medical Care AG & Co. KGaA
  • Getinge AB
  • Kestra Medical Technologies Inc.
  • Lepu Medical Technology Co., Ltd.
  • LivaNova PLC
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • Olympus Corporation
  • Penumbra, Inc.
  • Romsons Group
  • Shandong Weigao Group Medical Polymer Co., Ltd.
  • Smiths Medical PM Inc.
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
  • Vygon SA
  • ZOLL Medical Corporation
Product Code: MRR-037F3DB25943

The Implantable Cardioverter Defibrillators Market was valued at USD 5.00 billion in 2025 and is projected to grow to USD 5.28 billion in 2026, with a CAGR of 6.28%, reaching USD 7.66 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.00 billion
Estimated Year [2026] USD 5.28 billion
Forecast Year [2032] USD 7.66 billion
CAGR (%) 6.28%

A concise framing of how device innovation, evolving clinical practice, and health system pressures are reshaping the role and delivery of ICD therapy

Implantable cardioverter defibrillators (ICDs) are a cornerstone of modern cardiac care, providing life-saving therapy to patients at risk of sudden cardiac death. Over the past decade, device design, implantation techniques, and adjunctive monitoring have evolved significantly, driven by advances in materials science, battery technology, sensing algorithms, and remote connectivity. These innovations have reshaped patient selection, follow-up paradigms, and clinical outcomes, while creating new intersections between electrophysiology, device engineering, and digital health.

As the clinical landscape becomes more complex, stakeholders across hospitals, clinics, and ambulatory surgical centers must reconcile evolving evidence with operational realities. The interplay between primary and secondary prevention indications has become more nuanced, with refined risk stratification informing who benefits most from implantation. Concurrently, technology shifts such as MRI compatibility and remote monitoring have expanded device utility, but also introduced new considerations for device longevity, interoperability, and data governance. The resulting environment requires decision-makers to balance clinical efficacy, patient safety, and economic sustainability while navigating regulatory and reimbursement dynamics.

How converging technological breakthroughs, evolving clinical protocols, and care delivery shifts are fundamentally redefining ICD therapy and provider priorities

ICD therapy is undergoing a period of transformative change driven by converging technological, clinical, and system-level forces. Miniaturization and subcutaneous designs are reducing procedural complexity and device-related infections, while advances in lead technology and sensing algorithms improve arrhythmia discrimination and reduce inappropriate therapy. Parallel to hardware innovation, software enhancements and cloud-enabled remote monitoring are enabling longitudinal data capture, facilitating proactive device management, and enhancing patient engagement through telehealth integrations.

Regulatory frameworks and clinical pathways are adapting to these advances, accelerating pathways for MRI-compatible systems and devices with enhanced remote capabilities, but also raising the bar for real-world evidence and long-term safety data. Health systems are responding by evolving care models; ambulatory surgical centers are increasingly performing elective ICD implants, while hospitals and specialized cardiac centers retain complex cases. Collectively, these shifts are changing procurement priorities, clinical workflows, and value assessments, demanding integrated strategies that align product design with the operational realities of contemporary cardiac care.

Examining how recent tariff policies and trade dynamics have reshaped supply strategies, cost pressures, and clinical access considerations across the ICD value chain

The cumulative impact of tariff actions and trade policy changes on the ICD ecosystem has introduced new layers of complexity for manufacturers, distributors, and health systems. Tariff fluctuations affect upstream component costs, including semiconductor chips, battery materials, and electronic subassemblies, thereby influencing procurement strategies and supplier diversification. In response, manufacturers are reassessing sourcing footprints and reevaluating supply contracts to mitigate exposure to trade-driven cost variability.

Downstream, hospitals and ambulatory surgical centers face pressure to preserve budgetary flexibility while maintaining access to the latest device technologies. The tension between cost containment and clinical necessity has prompted greater scrutiny of total cost of ownership, spare parts inventories, and lead times. In some cases, manufacturers are accelerating plans for regional manufacturing or localized assembly to reduce tariff impact and strengthen just-in-time delivery capabilities. These strategic shifts are accompanied by closer collaboration between commercial teams and clinical stakeholders to prioritize device allocations based on clinical urgency and outcome expectations. Ultimately, trade policy changes are not uniform in effect; their cumulative impact is mediated by contract structures, regulatory requirements, and the agility of supply chain strategies implemented by device makers and health systems alike.

Deep segmentation insights that connect product architecture, clinical indication, enabling technologies, and care settings to adoption drivers and strategic opportunities

Segmentation analysis reveals differentiated drivers of adoption and clinical utility across product types, therapeutic indications, enabling technologies, and care settings. Based on Product Type, the landscape includes Subcutaneous ICDs, Transvenous ICDs, and Wearable ICDs, each addressing distinct clinical needs: subcutaneous systems prioritize infection avoidance and reduced intravascular hardware, transvenous devices offer pacing therapies and deeper rhythm management capabilities, while wearable solutions serve as interim protection or as adjuncts for high-risk periods. Based on Indication, patient pathways are framed by Primary Prevention and Secondary Prevention paradigms, with decision algorithms emphasizing risk stratification, comorbidity profiles, and life expectancy considerations that inform candidacy and timing for implantation.

Based on Technology, MRI Compatible and Remote Monitoring Enabled devices redefine post-implant care and diagnostic confidence, as MRI compatibility reduces barriers to advanced imaging and remote monitoring supports proactive device management and early detection of complications. Based on End User, Ambulatory Surgical Centers, Cardiac Care Centers, Clinics, and Hospitals embody different procedural volumes, case complexity, and infrastructure capacities, which in turn influence purchasing criteria, service agreements, and clinical support needs. Understanding these intersecting segment dynamics is essential for targeting innovation efforts, designing differentiated commercial propositions, and aligning clinical training and support services with the environments where devices are implanted and managed.

Regional dynamics and differentiated adoption pathways that illuminate how reimbursement, regulatory maturity, and care delivery models shape ICD access and deployment

Regional dynamics underscore heterogeneous adoption patterns, reimbursement environments, and regulatory frameworks that shape ICD strategy by geography. In the Americas, established reimbursement pathways and high procedural volumes coexist with growing emphasis on cost containment and value-based procurement, prompting device providers to demonstrate comparative effectiveness and long-term performance. The Europe, Middle East & Africa region presents a mosaic of regulatory maturity and healthcare funding models, where some markets rapidly adopt advanced features such as MRI compatibility while others prioritize basic access and affordability, thus requiring differentiated market entry and pricing approaches.

In the Asia-Pacific region, rapid investment in cardiac infrastructure and increasing uptake of minimally invasive techniques are expanding indications for device therapy, but market heterogeneity remains pronounced across public and private systems. Across all regions, regional clinical networks, investigator-led registries, and local guidelines influence adoption curves and post-market evidence requirements. Manufacturers and health systems that tailor value propositions to regional nuances-balancing clinical performance, service models, and pricing-can better navigate reimbursement complexities and accelerate responsible access to device therapy.

Key competitive and strategic company trends highlighting where product innovation, partnerships, clinical evidence, and supply resilience create commercial advantage

Competitive dynamics in the ICD space are characterized by sustained investment in incremental innovation, strategic partnerships, and selective consolidation. Established manufacturers continue to invest in next-generation lead designs, battery chemistries, and sensing algorithms to extend device longevity and reduce adverse events, while newer entrants and smaller firms are focusing on niche innovations such as wearable defibrillators and software-centric monitoring platforms that integrate with care management systems. Strategic collaborations between device companies and digital health firms are accelerating features like predictive analytics and remote monitoring dashboards, which can shift value conversations from device alone to bundled care solutions.

At the same time, intellectual property portfolios and clinical evidence generation remain pivotal competitive levers; firms that can demonstrate long-term safety and real-world effectiveness through registries and post-market studies gain negotiating power with payers and procurement teams. Supply chain resilience and manufacturing flexibility also differentiate competitors, particularly in a climate where trade policy and component scarcity can affect availability. For commercial teams, the competitive imperative is to align product roadmaps with service offerings and clinical support that address the full lifecycle of device use from implantation through long-term follow-up.

Practical strategic priorities that align clinical evidence generation, product design, and supply chain agility to accelerate adoption and preserve commercial resilience

Industry leaders should adopt an integrated approach that aligns product development, clinical evidence strategies, and supply chain resilience to secure sustainable advantage. Prioritize investments in technologies that demonstrably reduce procedural complications and improve patient experience, while ensuring that clinical trials and registries are designed to capture endpoints that matter to payers and providers. Concurrently, diversify sourcing strategies and consider regional assembly or contract manufacturing to mitigate exposure to tariff and trade policy volatility while maintaining quality and regulatory compliance.

Commercial strategies should emphasize bundled value propositions that combine devices with remote monitoring services and clinician support, enabling clearer demonstrations of outcome improvements and total cost implications for health systems. Strengthen collaboration with centers of excellence and clinician champions to accelerate uptake and to co-create training programs that lower the barrier to adoption in ambulatory settings. Finally, invest in data interoperability and cybersecurity measures to ensure that remote monitoring and device data can be integrated into electronic health records and care pathways securely, thereby increasing clinician trust and patient acceptance.

A transparent, clinician-informed research methodology combining expert interviews and systematic secondary review to ensure robust, actionable insights

The research underpinning this report combined primary qualitative engagement with clinical and commercial experts and secondary synthesis of peer-reviewed literature, regulatory filings, and clinical trial registries to ensure a balanced and evidence-based perspective. Primary engagements included interviews with electrophysiologists, device clinic managers, procurement professionals, and supply chain leaders to capture real-world practice patterns and decision criteria. Secondary sources were systematically reviewed for technology assessments, safety profiles, and comparative analyses to triangulate insights and validate thematic findings.

Analytical rigor was maintained through cross-validation of interview findings against published clinical guidelines and regulatory approvals. Limitations were acknowledged where high-quality long-term data are still emerging, particularly for newer subcutaneous and wearable solutions. The methodology emphasized transparency in source attribution and applied qualitative synthesis to translate heterogeneous data into actionable implications for stakeholders. Quality assurance processes included internal peer review and methodological checks to reduce bias and ensure the relevance of conclusions for commercial and clinical decision-making.

A concise synthesis capturing the strategic balance of innovation, evidence, and operational readiness required to advance ICD therapy responsibly and effectively

The implantable cardioverter defibrillator landscape is at an inflection point characterized by meaningful technological progress, shifting care delivery models, and heightened attention to supply chain and policy risks. Advances in device design and remote capabilities offer clear opportunities to improve patient outcomes and streamline follow-up, yet realizing these benefits requires aligned evidence generation, adaptable commercial strategies, and resilient operations. Health systems and manufacturers that proactively bridge clinical needs with pragmatic service models will be best positioned to deliver value while managing cost and access pressures.

Looking ahead, the successful commercialization of ICD innovations will depend on credible long-term safety data, interoperable digital ecosystems, and partnerships that integrate devices into broader care pathways. By focusing on these priorities, stakeholders can navigate regulatory complexity, address payer expectations, and expand responsible access to life-saving therapy across diverse healthcare environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Implantable Cardioverter Defibrillators Market, by Product Type

  • 8.1. Subcutaneous ICDs
  • 8.2. Transvenous ICDs
  • 8.3. Wearable ICDs

9. Implantable Cardioverter Defibrillators Market, by Indication

  • 9.1. Primary Prevention
  • 9.2. Secondary Prevention

10. Implantable Cardioverter Defibrillators Market, by Technology

  • 10.1. MRI Compatible
  • 10.2. Remote Monitoring Enabled

11. Implantable Cardioverter Defibrillators Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Care Centers
  • 11.3. Clinics
  • 11.4. Hospitals

12. Implantable Cardioverter Defibrillators Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Implantable Cardioverter Defibrillators Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Implantable Cardioverter Defibrillators Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Implantable Cardioverter Defibrillators Market

16. China Implantable Cardioverter Defibrillators Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Angiplast Pvt Ltd.
  • 17.7. Atrium Medical, Inc.
  • 17.8. B. Braun Melsungen AG
  • 17.9. Baxter International Inc.
  • 17.10. Becton, Dickinson and Company
  • 17.11. BIOTRONIK SE & Co. KG
  • 17.12. Boston Scientific Corporation
  • 17.13. Cardinal Health, Inc.
  • 17.14. ConMed Corporation
  • 17.15. ConvaTec Group PLC
  • 17.16. Cook Medical Inc.
  • 17.17. Fresenius Medical Care AG & Co. KGaA
  • 17.18. Getinge AB
  • 17.19. Kestra Medical Technologies Inc.
  • 17.20. Lepu Medical Technology Co., Ltd.
  • 17.21. LivaNova PLC
  • 17.22. Medtronic plc
  • 17.23. Merit Medical Systems, Inc.
  • 17.24. MicroPort Scientific Corporation
  • 17.25. Olympus Corporation
  • 17.26. Penumbra, Inc.
  • 17.27. Romsons Group
  • 17.28. Shandong Weigao Group Medical Polymer Co., Ltd.
  • 17.29. Smiths Medical PM Inc.
  • 17.30. Stryker Corporation
  • 17.31. Teleflex Incorporated
  • 17.32. Terumo Corporation
  • 17.33. Vygon SA
  • 17.34. ZOLL Medical Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SUBCUTANEOUS ICDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SUBCUTANEOUS ICDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SUBCUTANEOUS ICDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TRANSVENOUS ICDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TRANSVENOUS ICDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TRANSVENOUS ICDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY WEARABLE ICDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY WEARABLE ICDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY WEARABLE ICDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRIMARY PREVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRIMARY PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRIMARY PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SECONDARY PREVENTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SECONDARY PREVENTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SECONDARY PREVENTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY MRI COMPATIBLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY MRI COMPATIBLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY MRI COMPATIBLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY REMOTE MONITORING ENABLED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY REMOTE MONITORING ENABLED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY REMOTE MONITORING ENABLED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY CARDIAC CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY CARDIAC CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY CARDIAC CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 43. AMERICAS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 47. NORTH AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 48. NORTH AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 49. NORTH AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. LATIN AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 53. LATIN AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 54. LATIN AMERICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. MIDDLE EAST IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 68. MIDDLE EAST IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. MIDDLE EAST IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. AFRICA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. ASEAN IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASEAN IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 85. ASEAN IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. GCC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GCC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. GCC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. GCC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. GCC IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPEAN UNION IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPEAN UNION IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPEAN UNION IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. BRICS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. BRICS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 100. BRICS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. G7 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. G7 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. G7 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. G7 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. G7 IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. NATO IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. NATO IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. NATO IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. NATO IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. NATO IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. UNITED STATES IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. UNITED STATES IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. UNITED STATES IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. CHINA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. CHINA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. CHINA IMPLANTABLE CARDIOVERTER DEFIBRILLATORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)